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Abstract
Background The second coronavirus disease (COVID-19) epidemic wave in the UK progressed aggressively and was char-
acterised by the emergence and circulation of variant of concern alpha (VOC 202012/01). The impact of this variant on in-
hospital COVID-19-specific mortality has not been widely studied. We aimed to compare mortality, clinical characteristics, 
and management of COVID-19 patients across epidemic waves to better understand the progression of the epidemic at a 
hospital level and support resource planning.
Methods We conducted an analytical, dynamic cohort study in a large hospital in South London. We included all adults 
(≥ 18 years) with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who required hospital admis-
sion to COVID-19-specific wards between January 2020 and March 2021 (n = 2701). Outcome was COVID-19-specific 
in-hospital mortality ascertained through Medical Certificate Cause of Death.
Results In the second wave, the number of COVID-19 admissions doubled, and the crude mortality rate dropped 25% (1.66 
versus 2.23 per 100 person-days in second and first wave, respectively). After accounting for age, sex, dexamethasone, oxygen 
requirements, symptoms at admission and Charlson Comorbidity Index, mortality hazard ratio associated with COVID-19 
admissions was 1.62 (95% CI 1.26, 2.08) times higher in the second wave.
Conclusions Although crude mortality rates dropped during the second wave, the multivariable analysis suggests a higher 
underlying risk of death for COVID-19 admissions in the second wave. These findings are ecologically correlated with an 
increased circulation of SARS-CoV-2 variant of concern 202012/1 (alpha). Availability of improved management, particu-
larly dexamethasone, was important in reducing risk of death.
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Introduction
Since its emergence in December 2019, the spread of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
has posed immense challenges for health care systems 
across the globe [1]. In the United Kingdom (UK) the first 
confirmed case was registered on 31 January 2020, but 
transmission rates increased quickly leading to the introduc-
tion of a series of control measures that escalated to a full 
national lockdown (23 March 2020). This was subsequently 
followed by a drop in transmission and hospitalisation rates 
with restrictions eased over the summer months. However, in 
October 2020 infections began to increase again leading to a 
second wave of coronavirus disease (COVID-19) cases. The 
implementation of a second lockdown (5 November 2020) 
followed by tiered control measures were needed to reduce 
the transmission rates again [2]. As of 1 May 2021, the UK 
has recorded 4,418,819 confirmed cases, 463,485 hospital 
admissions, and 127,571 deaths [3].
During the first wave of COVID-19, relatively little was 
known about this novel illness and patient management 
was largely based upon experience of treating other viral 
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infections. However, as new evidence became available, 
the standard of care of patients admitted with COVID-19 
changed. From the start of the second wave, dexametha-
sone was prescribed to all patients requiring supplemental 
oxygen and Remdesivir was administered to hypoxemic 
patients presenting within 10 days of symptoms onset. The 
indications for Tocilizumab changed during the second wave 
where patients initially had access to this only within clinical 
trials [4–8].
A key feature of the second wave of COVID-19 in the 
UK, was the emergence of a new SARS-CoV-2 variant des-
ignated VOC 202012/01 or alpha (lineage B.1.1.7). This new 
variant was identified in samples originally taken in South 
East England in early October 2020, and became the pre-
dominant variant circulating in the UK throughout the sec-
ond epidemic wave [9–11]. It is now established that VOC 
202012/01 is more transmissible than pre-existing variants 
and it is associated with an excess of all-cause mortality 
28 days after a positive test in the community [12–14]. 
However, the impact of this VOC on in-hospital COVID-
19-specific mortality remains poorly understood.
St George’s University Hospital NHS Foundation Trust 
is one of the largest hospitals in the UK and is based in 
South West London. It serves a local catchment population 
of 560,000 and specialist services to 3.4 million people. The 
objective of this study was to assess whether mortality of 
patients admitted for COVID-19 treatment was different in 
the second UK wave of COVID-19 compared to the first 
wave accounting for differences in the standard of care avail-
able in each wave.
Methods
Study design
This is a single-centre, analytical, dynamic cohort study 
using data extracted from routinely collected, electronic 
medical records and hospital database.
Participants and setting
The study population for this cohort study comprised all 
adults (≥ 18 years) with SARS-CoV-2 infection confirmed 
by polymerase chain reaction (PCR) and/or clinico-radiolog-
ical diagnosis of COVID-19, who required hospital admis-
sion to COVID-19-specific wards at St George’s University 
Hospitals NHS Foundation Trust (London, UK). Patients 
seen in the Emergency Department or in Acute Medical 
Units (AMU) who were discharged on the same day were 
not included. Although COVID-19 wards opened in March 
2020, the study period encompasses admissions between 
1 January 2020 and 31 March 2021, as some of the early 
patients admitted to COVID-19 wards were already hospi-
talised. All patients meeting the inclusion criteria during 
the study period were included in the cohort. There was no 
a priori study size calculation.
Data sources and measurement
The study cohort was identified retrospectively using hos-
pital records of admissions to active COVID-19 wards. 
These lists included patient identifiers, hospital admission 
date, ward and administrative information. Respiratory and 
intensive care clinicians within the study team and involved 
in the care of COVID-19 patients, reviewed the electronic 
medical records for all the patients in the initial list, confirm-
ing criteria for COVID-19 admission. In case of patients 
with multiple COVID-19 admissions, only the most severe, 
as defined by the highest respiratory support needed, was 
included [15].
Study follow-up was also carried out by clinicians, pro-
spectively, through review of electronic medical records. 
Patient data were extracted manually using a standardised 
electronic questionnaire and was supervised by a senior 
clinician within the respiratory team. Some data were also 
obtained through the informatic department and linked using 
hospital identifiers (laboratory, pathology results and ethnic-
ity data).
The follow-up period for this study began at admission 
and ended at outcome occurrence (death) or censoring. Par-
ticipants were censored at hospital discharge or at 6 months 
if admissions exceeded this period (one patient only).
PCR pathology results were available for all tests 
requested during the study period, so we matched these with 
our cohort of patients. Those with positive PCR results dated 
at least 15 days after their hospital admission were consid-
ered probable hospital acquired infections (HAI) and had the 
start of their follow-up (time at risk) amended to be 14 days 
(maximum incubation period [16]) before the date of the 
positive PCR result, instead of the actual admission day.
Variables
The outcome variable was in-hospital COVID-19-associated 
mortality (as cause or contributor), ascertained from clinical 
records and Medical Certificate Cause of Death (MCCD). 
The main explanatory variable for this analysis was COVID-
19 wave, and 31 June 2020 used as cutoff to separate both 
waves. UK Office for National Statistics estimated the end 
of the first wave at the end of May 2020, and the begin-
ning of the second wave at the beginning of September 2020 
[17]. There were three patients admitted between these dates 
(Fig. 1), two admissions at the beginning June 2020 were 
considered first wave, and one at the end of August 2020 was 
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considered second wave. First wave was used as baseline/
reference.
Covariates of interest for this analysis included demo-
graphics (sex, age at admission, ethnicity), symptoms at 
admission, body mass index (BMI), treatment (dexameth-
asone, Remdesivir, Tocilizumab), oxygen requirement, 
HFNO/CPAP (high flow nasal oxygen/continuous positive 
airway pressure administered only in specialist wards), 
invasive ventilation, COVID-19 pneumonitis admitted to 
Intensive Care Unit (ICU) admission, Clinical Frailty Score 
(CFS), Charlson Comorbidity Index (CCI). Most variables 
were used in their original scale, others were recategorised 
using clinically relevant categories with a sufficient number 
of participants in each group to avoid sparsity.
Where categorised, age groups in years were: 18–39, 
40–59, 60–79, ≥ 80. BMI at admission was grouped using 
categories derived from the WHO classification of BMI 
(in kg/m2): < 18.5, 18.5–24.9, 25–29.9,  ≥ 30 [18]. Oxygen 
requirement was a dichotomous variable indicating whether 
the maximum FiO2 (Fraction of Inspired Oxygen) was over 
21%. Symptoms at admission were respiratory or wider 
infective symptoms at time of presentation. The CFS level 
was collected on a nine-point ordinal scale to assess frailty 
within 2 weeks of admission, but to avoid sparsity catego-
ries seven to nine were grouped [19]. CFS was expanded 
to include all age groups excepting those patients with dis-
abilities which rendered it inappropriate. CCI is a widely 
used comorbidity summary measure, based on age and a 
predefined number of conditions with an assigned integer 
weight representing the severity of each condition; for this 
analysis, scores of eight or more were grouped in one cat-
egory [20]. Individual comorbidities were not included to 
avoid collinearity with CCI. All scores were calculated by 
clinicians experienced in the use of scales.
Statistical methods
The distribution of covariates was assessed for the entire 
cohort and across waves. Chi-square test was used to assess 
independence. Mortality rates and person-time of obser-
vation were calculated for the main exposure groups and 
all covariates of interest. The strength of the association 
was quantified using incidence rate ratios (IRR), and the 
Fig. 1  Number of admissions per day according to outcome
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statistical significance using 95%CIs and p values. Survival 
across the different waves was explored using time-to-event 
analysis and log-rank to test the significance of the differ-
ence between the survival curves.
Rates were modelled using Cox regression for the mul-
tivariable analysis. Proportional hazard assumption was 
supported (graphically and by testing for a zero slope in 
Schoenfeld residuals).
A causal model was built using a stepwise backward 
approach where (non-forced) pre-defined covariates were 
retained in the model unless there were problems with mul-
ticollinearity. Age and gender were considered a priori con-
founders (forced variables). Age was fitted using restricted 
cubic splines, with knots positioned so numbers of events 
between knots were approximately equally distributed. The 
full model included age, gender and all variables found to 
confound the crude association between wave and mortality 
(non-forced variables). A change in the magnitude ≥ 5.5% 
was considered an indication of confounding. ICU admis-
sion was included in the model as a non-forced variable 
regardless of the degree of confounding of the main asso-
ciation. Problems with multicollinearity on the main effect 
in the full model, were resolved using RMSE (Root Mean 
Square Error) reduction for backward deletion of non-forced 
variable, with RMSE for the full model used as reference for 
each step [21].
Following the same methodology, we did a sub-analysis 
among those requiring ICU admission. Data management 
and statistical analysis were carried out using R (R Core 
Team version 3.6.3, Vienna, Austria).
Governance and ethics
This study was approved by the Health Research Authority 
(20/SC/0220). This manuscript follows the STROBE state-
ment for reporting of cohort studies.
Results
Participants
Between 1 January 2020 and 31 March 2021, there were 
3376 COVID-19 positive adult patients registered at St. 
Georges Hospital. Of these, 2701 were patients admitted to 
COVID-19 wards for treatment, all of whom were included: 
32.7% (884 of 2701) in the first wave and 67.3% (1817 of 
2701) in the second wave (Fig. 1). At the time of database 
lock  (23rd May 2021), there were 16 patients (all admitted 
during the second wave) with no outcome recorded.
The distribution of characteristics at admission for the 
entire cohort and across waves is shown in Table 1. COVID-
19 patients admitted during the second wave were more 
likely to be younger with intermediate levels of frailty: CFS 
3 to 5 were more prevalent in the second wave (1103 of 
1817, 60.7%) than in the first wave (392 of 884, 44.3%). 
Admissions scoring zero to 3 in CCI were more prevalent 
during the second wave (891 of 1817, 49.0% vs. 386 of 884, 
43.7%). Absence of respiratory or wider infective symptoms 
at onset (i.e., hospital acquired infections with initial diag-
nosis through PCR) was more prevalent in the second wave 
(361, 19.9%) compared to the first wave (50, 5.7%).
The distribution of medical interventions after admis-
sion is listed in Table 2. The prevalence of admitted patients 
requiring oxygen during admission was similar in both 
waves, but the use of HFNO/CPAP was more prevalent in 
the second wave whilst invasive ventilation was more preva-
lent in the first wave. The distribution of patients requiring 
ICU admission had a similar distribution across waves (263 
of 2701, 23.1%). The use of dexamethasone, Remdesivir and 
Tocilizumab was almost exclusive during the second wave.
Outcome and follow‑up time
A total of 752 patients died over the total time at risk (40,777 
person-days); 297 of 884 (33.6%) deaths occurred during 
the first wave and 455 of 1801 (25.3%) during the second 
wave. The median time of follow-up for those discharged 
was 10 days (IQR: 5–22 days) and for those who died was 
11 days (IQR: 5–19 days). We found no differences in the 
overall distribution of the follow-up time across waves. 
Among those discharged, admissions with lengths of stay 
(LOS) over 35 days were similar across waves (74 of 587, 
11.9% for the first wave and 150 of 1346, 11.1% for the 
second); LOS between 0 and 7 days were more prevalent in 
the second wave (562 of 1346, 41.8%) than in the first wave 
(188 of 587, 32.0%). The median probability of survival was 
29 days (95% CI 30–41 days) for the first wave, and 37 days 
(95% CI 32–47 days) for the second.
Main results
In this cohort, patients admitted during the second wave of 
the COVID-19 pandemic, had a (crude) mortality rate 25% 
lower than that of patients admitted during the first wave 
(IRR 0.75, 95% CI 0.64, 0.86). Mortality rates, and crude 
IRR for all variables of interest are shown in Table 1 of the 
supplementary materials. Overall, mortality rates were 1.19 
times higher in men than in women (95% CI 1.03, 1.38) 
and 1.37 times higher in patients of Asian ethnicity com-
pared to white ethnicity (95% CI 1.12, 1.67). Crude IRR 
was 1.92 times higher (95% CI 1.27, 3.09) among those 
aged 60–79 years, and 2.81 times (95% CI 1.85, 4.50) in 
those aged over 80 years compared to patients younger than 
40 years. Mortality increased with increasing levels of frailty 
(CFS and CCI).
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Table 3 shows the crude and adjusted IRR (IRRa) for the 
effect of wave on mortality on the same set of observations. 
The strongest confounders of the association in this cohort 
were dexamethasone, oxygen requirement, symptomatic at 
admission, CCI, and HFNO/CPAP. Mortality was 43% (95% 
CI 71%, 52%) lower in the second wave compared to the first 
wave when adjusting for the effect of dexamethasone; and 
16% (95% CI 3%, 27%) lower when adjusting for oxygen 
requirement. Thus, oxygen requirement is acting as partial 
positive confounder whereas dexamethasone is acting as a 
negative confounder in this cohort.
In the multivariable analysis, the hazard of death dur-
ing the second wave was 1.62 times higher (95% CI 1.26, 
2.08) than during the first wave, after conditioning on age, 
sex, dexamethasone, oxygen requirement, symptoms at 
admission, and CCI. With age fitted as a flexible spline, 
and accounting for all the variables in this model, males 
had HR 1.21 (95% CI 1.04, 1.40); those presenting with 
symptoms at admission a HR 1.72 (95% CI 1.35, 2.20) and 
increasing CCI was (non-linearly) associated with increas-
ing hazards of death. Dexamethasone reduced the hazard 
Table 1  Baseline characteristic 
of the study population and 
comparison groups
p value corresponds to the chi square test of independence
Variable Categories First wave Second wave Total p value
N = 884 (100.0%) N = 1817 (100.0%) N = 2701 (100.0%)
Sex Female 363 (41.1%) 782 (43.0%) 1145 (42.4%) 0.330
Male 521 (58.9%) 1035 (57.0%) 1556 (57.6%)
Age 18–39 71 (8.0%) 147 (8.1%) 218 (8.1%) 0.001
Grouped 40–59 190 (21.5%) 495 (27.2%) 685 (25.4%)
(years) 60–79 350 (39.6%) 724 (39.8%) 1074 (39.8%)
 ≥ 80 273 (30.9%) 451 (24.8%) 724 (26.8%)
Ethnicity White 301 (34.0%) 636 (35.0%) 937 (34.7%)  < 0.001
Asian 145 (16.4%) 346 (19.0%) 491 (18.2%)
Black 143 (16.2%) 252 (13.9%) 395 (14.6%)
Other 147 (16.6%) 491 (27.0%) 638 (23.6%)
Unknown 148 (16.7%) 92 (5.1%) 240 (8.9%)
Clinical 1: Very fit 94 (10.6%) 102 (5.6%) 196 (7.3%)  < 0.001
Frailty 2: Fit 119 (13.5%) 173 (9.5%) 292 (10.8%)
Score (CFS) 3: Managing well 217 (24.5%) 685 (37.7%) 902 (33.4%)
4: Vulnerable 93 (10.5%) 234 (12.9%) 327 (12.1%)
5: Mildly frail 82 (9.3%) 184 (10.1%) 266 (9.8%)
6: Moderately frail 114 (12.9%) 241 (13.3%) 355 (13.1%)
7–9: Severely frail 164 (18.6%) 197 (10.8%) 361 (13.4%)
Missing 1 (0.1%) 1 (0.1%) 2 (0.1%)
Charlson 0 90 (10.2%) 207 (11.4%) 297 (11.0%) 0.232
Comorbidity 1 82 (9.3%) 209 (11.5%) 291 (10.8%)
Index (CCI) 2 112 (12.7%) 227 (12.5%) 339 (12.6%)
3 102 (11.5%) 248 (13.6%) 350 (13.0%)
4 132 (14.9%) 237 (13.0%) 369 (13.7%)
5 127 (14.4%) 222 (12.2%) 349 (12.9%)
6 104 (11.8%) 194 (10.7%) 298 (11.0%)
7 59 (6.7%) 130 (7.2%) 189 (7.0%)
8_over 76 (8.6%) 143 (7.9%) 219 (8.1%)
BMI  < 18.5 49 (5.5%) 80 (4.4%) 129 (4.8%)  < 0.001
Grouped 18.5–24.9 258 (29.2%) 527 (29.0%) 785 (29.1%)
(kg/m2) 25–29.9 230 (26.0%) 559 (30.8%) 789 (29.2%)
 ≥ 30 206 (23.3%) 528 (29.1%) 734 (27.2%)




No 50 (5.7%) 361 (19.9%) 411 (15.2%)  < 0.001
Yes 834 (94.3%) 1456 (80.1%) 2290 (84.8%)
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of death by 53% (95% CI 40%, 63%) when accounting for 
all the other factors in the model.
In the subgroup analyses of COVID-19 patients requiring 
ICU, the hazard of death during the second wave was 2.00 
(95% CI 1.10, 3.62) after conditioning on age, sex, dexa-
methasone, Remdesivir, Tocilizumab, and HFNO/CPAP. A 
summary of model development is presented in the supple-
mentary materials.
Discussion
This cohort study examined differences in the risk of death 
of patients requiring in-hospital treatment for COVID-19, 
during the first and second wave of the COVID-19 pandemic 
in UK.
The number of COVID-19 admissions was 2.05 times 
higher in second wave compared to the first wave (1817 vs. 
884) and the crude mortality rate was 25% (95%CI 14%, 
36%) lower for those admitted during the second wave.
We summarised the distribution of baseline characteris-
tics at admission and medical interventions across waves for 
the entire study cohort (Table 1). During the second wave, 
younger admissions with moderate levels of frailty/CCI 
Table 2  Distribution of medical 
interventions after admission 
across waves
ICU Intensive Care Unit, HFNO/CPAP high flow nasal oxygen/continuous positive airway pressure
p value corresponds to the χ2 test of independence
Variable/Categories First wave Second wave Total p value
N = 884 (100.0%) N = 1817 (100.0%) N = 2701 (100.0%)
ICU admission 211 (23.9%) 412 (22.7%) 623 (23.1%) 0.489
Oxygen requirement 668 (75.6%) 1328 (73.1%) 1996 (73.9%) 0.148
Oxygen requirement missing 9 (1.0%) 11 (0.6%) 20 (0.7%)
HFNO/CPAP 81 (9.2%) 400 (22.2%) 481 (17.8%)  < 0.001
HFNO/CPAP missing 9 (1.0%) 18 (1.0%) 27 (1.0%)
Invasive ventilation 178 (20.1%) 237 (13.0%) 415 (15.4%)  < 0.001
Invasive ventilation missing 6 (0.7%) 10 (0.6%) 16 (0.6%)
Dexamethasone 58 (6.6%) 1241 (68.3%) 1299 (48.1%)  < 0.001
Tocilizumab 23 (2.6%) 229 (12.6%) 252 (9.3%)  < 0.001
Remdesivir 0 (0.0%) 575 (31.6%) 575 (21.3%)  < 0.001
Table 3  Crude (IRRc) and 
adjusted IRR (IRRa) for the 
effect of wave on mortality
Covariates above the dotted line are those change in the magnitude of the effect was ≥ 5.5%
IRRc crude RR, IRRa adjusted RR, ICU Intensive Care Unit, HFNO/CPAP high flow nasal oxygen/con-
tinuous positive airway pressure
Covariate N Missing IRRc IRRa 95%CI IRRa IRRa 95%CI
Dexamethasone 2685 0 0.75 (0.64, 0.86) 0.57 (0.48, 0.69)
Oxygen requirement 2665 20 0.75 (0.65, 0.87) 0.84 (0.73, 0.97)
Symptomatic at admission 2685 0 0.75 (0.64, 0.86) 0.85 (0.73, 0.98)
Charlson Comorbidity Index (CCI) 2685 0 0.75 (0.64, 0.86) 0.70 (0.61, 0.82)
HFNO/CPAP 2658 27 0.73 (0.63, 0.84) 0.69 (0.59, 0.80)
Ventilation 2669 16 0.74 (0.64, 0.86) 0.78 (0.67, 0.90)
Remdesivir 2685 0 0.75 (0.64, 0.86) 0.76 (0.65, 0.89)
ICU admission 2685 0 0.75 (0.64, 0.86) 0.76 (0.66, 0.88)
Tocilizumab 2685 0 0.75 (0.64, 0.86) 0.73 (0.63, 0.85)
Clinical frailty score (CFS) 2683 2 0.75 (0.64, 0.86) 0.76 (0.65, 0.88)
Ethnicity 2685 0 0.75 (0.64, 0.86) 0.74 (0.64, 0.86)
BMI grouped (kg/m2) 2421 264 0.88 (0.74, 1.04) 0.89 (0.75, 1.05)
Age grouped (years) 2685 0 0.75 (0.64, 0.86) 0.75 (0.65, 0.87)
Sex 2685 0 0.75 (0.64, 0.86) 0.75 (0.65, 0.87)
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were more prevalent, compared to either older and/or frailer 
patients in the first wave. COVID-19 vaccination program 
(which began in England on 8 December 2020), is likely to 
have impacted the characteristics of hospitalised patients. 
National cumulative data up to week ending 28 March 2021 
showed an overall vaccine uptake in the population of 42.2% 
for dose one and 4.7% for dose number two. Uptake among 
those aged ≥ 80 years was 94.3% for dose one and 40.5% for 
dose number two; in younger age groups uptake was lower 
concordant with prioritisation of target groups for vaccina-
tion [22, 23]. This could explain some of the observed differ-
ences in the distribution of age across waves in our cohort.
In addition to this, during the second wave, we observed 
an increase of COVID-19-specific treatments as trial data 
emerged for the use of dexamethasone, Remdesivir and 
Tocilizumab.
The multivariable analysis attempted to account for all the 
available factors unequally distributed across waves and also 
associated with mortality (while avoiding multicollinearity 
in the model).We found a 1.62-fold increase in the hazard 
of death (95%CI 1.26, 2.08) in the second wave compared 
to the first wave, after controlling for the effect of age, sex, 
dexamethasone, oxygen requirement, symptoms at admis-
sion and CCI.
The multivariable model includes two highly correlated 
variables: dexamethasone therapy and oxygen requirement. 
These are highly correlated as the benefits of dexametha-
sone in the management of COVID-19 hospitalised patients 
have been shown only for patients with hypoxaemia, but 
not among those with milder disease (without hypoxaemia) 
[24, 25]. This correlation was only observed in the second 
wave in accordance with changes in the standard of care 
as evidence became available. In this cohort, the observed 
proportion of those who survived among those receiving 
both oxygen and dexamethasone was similar across waves: 
75.5% (37 of 51) during the first wave, and 70.5% (866 of 
1228) during the second wave. However, the individual dis-
tribution of these two variables was different across waves 
(Table 2). Therefore, both variables were included in the 
model, as the level of uncontrolled confounding reduced was 
larger than the error introduced due to collinear effects. In 
the final model, dexamethasone reduced the hazard of death 
in this population of patients by 53%, 95% CI 40%, 63% 
(after accounting for the effect of age, sex, oxygen require-
ment, symptoms at admission, CCI and wave).
We further explored the effect of wave on mortality on 
the subpopulation of patients admitted to ICU, i.e., the most 
severe COVID-19 patients. All these patients had oxygen 
therapy so, this variable was not a factor in the main model. 
Within this sub-group of patients, the hazard of death dur-
ing the second wave was also larger than in the first wave 
(HR: 2.00, 95% CI 1.10, 3.62) after accounting for the effect 
of age, sex, dexamethasone, Remdesivir, Tocilizumab and 
HFNO/CPAP. This further supports the observation that risk 
of death in COVID-19 hospitalised patients was higher in 
the second wave compared to the first wave, when differ-
ences in the standard of care and the characteristics of the 
patients were taken into account.
There is evidence that VOC 202012/01 (alpha) is associ-
ated with increased risk of death in the community [12–14]; 
but since S-gene target failure (SGTF) detection or genomic 
sequencing data were not available for this study population, 
attributing our observation of increased in-hospital mortal-
ity to variant VOC 202012/01 would largely depend on the 
acceptability of the assumption that said variant was domi-
nant in our catchment area. This might not be an unreason-
able assumption, as community prevalence of SGTF (asso-
ciated with this new variant), was already at 5.8% at the 
beginning of November 2020, increasing sharply to reach 
94.3% at the end of January 2021 [13]; which correlates 
with the distribution of second wave admissions (Fig. 1). 
Supporting this, aggregated St. Georges Hospital data found 
84.2% (981 of 1165) of SARS-CoV-2 isolates sequenced 
between 26 November and 20 February 2021, to be the alpha 
VOC.
Strengths and limitations
This was a large analytical cohort study comparing groups 
of patients at different points in time. The overall goal was to 
investigate if different standards of care and possible changes 
in the natural history of the disease (attributed to changes in 
SARS-CoV-2 variants), had an impact on in-hospital mortal-
ity. We included all patients admitted to COVID-19 wards 
for treatment.
All variables used in this study were extracted prospec-
tively from electronic medical records ensuring data col-
lected were the same across waves. Most of the data were 
collected by experienced respiratory and ICU clinicians, 
and although data inconsistencies were verified during data 
management, misclassification of covariates due transcrip-
tion errors cannot be ruled out. Additionally, unmeasured 
variables and/or coarse categorisation (e.g., oxygenation 
parameters) could have introduced residual confounding.
Overall, there was a good level of data completeness with 
only BMI observing large numbers of missing values. Data 
were collected from electronic medical records and a greater 
number of BMI measurements were not recorded in the first 
wave as staff were dealing with unprecedented numbers of 
patients at that time. Across both waves, the proportion of 
missing values was larger for those with shorter LOS and 
among those who died. We assessed confounding on com-
plete cases to avoid biasing the estimate.
Outcome and date of outcome were collected separately 
and ascertained from MCCD (available for 749 of 752 
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deaths, 99.6%). The number of deaths we observed dur-
ing the first wave is consistent with numbers previously 
reported for the same catchment area and period [26]. 
However, it has been observed that during the first epi-
demic wave in the UK there was a larger mortality within 
care homes [2], so it is possible that we have underesti-
mated the number of deaths in the first wave. This differ-
ential misclassification of outcome could have led to an 
overestimation of the effect of the second wave. In addi-
tion, temporal effects could also have explained some of 
the observed differences between waves, as fatality rates 
are known to be higher during winter months, when the 
second wave unfolded.
This study was looking at a population of hospitalised 
adults with COVID-19 in a large reference teaching London 
hospital. We observed a second wave of admissions twice 
as large as the first one, which is consistent with national 
aggregated figures of hospitalisations [3]. The overall demo-
graphic characteristics of our cohort (age, sex distribution) 
are similar to those reported on a large national cohort of 
patients with COVID-19 admitted to 208 acute care hospitals 
across England, Wales and Scotland during the growth phase 
of the first wave [27]. ISARIC WHO CCP-UK reported 17% 
of ICU admissions and at least, 26% mortality in their cohort 
(34% patients were in-hospital with no reported outcome, 
at the time of publication). In our study, we observed larger 
proportions of both ICU admissions (23.1%, 211 of 884) and 
deaths (33.6%, 297 of 884) on a comparable period. These 
differences could be explained in part, by a possible under-
estimation of deaths among ISARIC admissions with longer 
LOS, more likely to be sickest (as noted by the authors [27]). 
In addition, St. Georges Hospital was a regional ICU centre 
and accepted intubated patients from other hospitals who 
had run out of ICU capacity, resulting in a population biased 
towards severity. Our results apply only to an inpatient popu-
lation, but generalisability will be limited by regional char-
acteristics and factors affecting the force of infection.
Conclusion
Analysis of COVID-19 admissions recorded in St. Georges 
Hospital between 01 January 2020 and 31 March 2021, 
shows a second epidemic wave twice as large as the first 
one. Although crude rates would indicate a lower in-hospital 
mortality during the second wave; accounting for differ-
ences in the distribution of protective and risk factors (age, 
sex, dexamethasone use, oxygen requirement, symptoms 
at admission and comorbidities), suggests a higher risk of 
death during the second epidemic wave compared to the 
first. Our findings are temporally and ecologically correlated 
with an increased circulation of VOC 202012/01 (alpha), 
with estimates in agreement community-based studies. The 
availability of improved management and new treatments, 
particularly dexamethasone, was important in reducing risk 
of death during the second wave. Our findings highlight the 
importance of understanding the hospital burden of COVID-
19 and the outcomes associated with new circulating SARS-
CoV-2 variants.
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